Bioksa - Company finances
|
EUR
|
2019
From: 2019-01-28
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|
|
Financial data
|
|||||||
| Sales revenue | 3,322 | 7,042 | 131,053 | 412,866 | 1,022,540 | 1,007,000 | 896,506 |
| Profit before tax | 1,180 | -17,426 | 64,007 | 186,720 | 97,353 | 101,042 | 62,633 |
| Net profit | 1,121 | -17,426 | 64,007 | 186,720 | 96,343 | 101,042 | 62,633 |
| Equity | 66,123 | 866 | 69,506 | 256,226 | 350,594 | 451,636 | 514,269 |
| Liabilities | 18,931 | - | - | 256,262 | 636,202 | 205,492 | 511,750 |
| Non-current assets | 8,700 | 8,700 | 123,574 | 433,430 | 341,060 | 288,870 | 288,870 |
| Current assets | 86,057 | 71,175 | 103,504 | 162,900 | 667,187 | 470,638 | 922,605 |
| Total assets | 94,757 | 79,875 | 227,078 | 596,330 | 1,008,247 | 759,508 | 1,211,475 |
|
Taxes paid
|
|||||||
| STI taxes | - | - | - | - | 1,760 | - | - |
| Social insurance contributions | - | - | - | - | 5,735 | 19,995 | 32,365 |
|
Financial indicators
|
|||||||
| Revenue change y/y | - | +112.0% | +1761.0% | +215.0% | +147.7% | -1.5% | -11.0% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 1.2% | -21.8% | 28.2% | 31.3% | 9.6% | 13.3% | 5.2% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 1.7% | -2012.2% | 92.1% | 72.9% | 27.5% | 22.4% | 12.2% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 33.7% | -247.5% | 48.8% | 45.2% | 9.4% | 10.0% | 7.0% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 35.5% | -247.5% | 48.8% | 45.2% | 9.5% | 10.0% | 7.0% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.3 | - | - | 1.0 | 1.8 | 0.5 | 1.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 1,107 | 2,608 | 25,641 | 107,705 | 250,420 | 134,267 | 95,204 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Bioksa - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2026-05-17 | 2026-05-18 | 3041.81 |
| 2023-07-19 | 2023-07-20 | 843.94 |
| 2023-01-20 | 2023-01-22 | 465.89 |
| 2023-01-17 | 2023-01-19 | 465.60 |
| 2022-05-17 | 2022-05-17 | 286.62 |
| 2022-05-04 | 2022-05-10 | 649.98 |
| 2022-05-03 | 2022-05-03 | 667.72 |
Bioksa - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-02-21 | 2026-02-21 | 0.26 |
| 2024-11-17 | 2024-11-18 | 514.1 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Bioksa, MB (code 305003416) is a Small partnership engaged in Research and development in technical sciences. In financial year 2025, the company generated revenue of €896.5K and net profit of €62.6K, with a profit margin of 7.0%. Revenue declined by 11.0% year on year and by 12.3% over two years, after reaching €1.02M in 2023 and €1.01M in 2024. Profitability also softened from €96.3K in 2023 to €101.0K in 2024, before easing to €62.6K in 2025. At the balance sheet date, total assets stood at €1.21M, equity at €514.3K and liabilities at €511.8K. The equity ratio was 42.5% and debt-to-equity was 1.00, indicating a broadly balanced capital structure. Asset turnover reached 0.74x, while ROE was 12.2% and ROA 5.2%. Revenue per employee was €99.6K and profit per employee €7.0K, suggesting moderate operating productivity in 2025.